icon-folder.gif   Conference Reports for NATAP  
 
  ID Week 2025
October 19-22
Atlanta, GA

Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1
 
 
  IDWeek; Atlanta, Georgia, and online; October 19-22, 2025

1024251

1024252

1024253

1024254

1024255

1024256

1024257

1024258

1024259

10242510

10242511

10242512